Cancer remains a leading cause of global mortality, with increasing incidence and limited therapeutic options for advanced-stage disease. Accumulating evidence indicates that mitochondrial reprogramming is a key regulator of cancer biology, coordinating energy metabolism, oxidative stress, epigenetic remodeling, and...
K. Liu, Xin-Yue Cui, Li-Min Gan et al.· Cell Communication and Signa...· 0 citations
Immune checkpoint inhibitors (ICIs) have reshaped systemic therapy for hepatocellular carcinoma (HCC), but durable benefit remains limited to a subset of patients because of tumor-intrinsic and microenvironmental mechanisms of immune resistance. Canonical epigenetic and epitranscriptomic alterations, including DNA meth...
Ya-Fei Zhi, Yan Guo, Hui-Fang Wei et al.· Clinical and Molecular Hepat...· 0 citations
The SF3b complex is positioned as a disease-modifying hub at the intersection of RNA splicing and cancer biology, and highlights the opportunities and challenges associated with therapeutically targeting spliceosome components in oncology.
Shulin Li, Li-Tong Shang, Jia-Yi Yang et al.· Blood Advances· 0 citations
A humanized CD70-targeted CAR-T cell therapy is developed, A174-hu1-CAR-T, with reduced fratricide and potent antitumor activity, providing a preclinical foundation to support further translational development.
Meng-Jia Zhang, Zhi-Hao Wang, Cheng Gao et al.· International Immunopharmaco...· 0 citations
It is demonstrated that MX1 promotes GC cell migration by suppressing ANXA2 ubiquitination and degradation, highlighting the critical role of the MX1-ANXA2 axis in GC progression.
Hang Yang, Huihan Ai, Zikun Wu et al.· Biochimica et Biophysica Act...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
